MSP2
MCID: INC033
MIFTS: 23

Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 2 (MSP2)

Categories: Bone diseases, Genetic diseases, Mental diseases

Aliases & Classifications for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

MalaCards integrated aliases for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 2:

Name: Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 2 12
Multisystem Proteinopathy 2 12
Ibmpfd2 12
Msp2 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0111384

Summaries for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Disease Ontology : 12 An inclusion body myopathy with Paget disease of bone and frontotemporal dementia that has material basis in heterozygous mutation in HNRPA2B1 on 7p15.2.

MalaCards based summary : Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 2, also known as multisystem proteinopathy 2, is related to inclusion body myopathy with early-onset paget disease with or without frontotemporal dementia 2 and human granulocytic anaplasmosis. The drugs Lumefantrine and Artemether have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and testes.

Related Diseases for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Graphical network of the top 20 diseases related to Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 2:



Diseases related to Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 2

Symptoms & Phenotypes for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Drugs & Therapeutics for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Drugs for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lumefantrine Approved Phase 4 82186-77-4 6437380
2
Artemether Approved Phase 4 71963-77-4 119380 68911
3
Artesunate Approved, Investigational Phase 4 88495-63-0 6917864 5464098
4
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
5
Primaquine Approved Phase 4 90-34-6 4908
6
Piperaquine Experimental, Investigational Phase 4 4085-31-8 5079497
7
Dihydroartemisinin Experimental, Investigational Phase 4 71939-50-9 6918483
8 Artemisinins Phase 4
9 Artemisinine Phase 4
10 Artemether, Lumefantrine Drug Combination Phase 4
11 Antiprotozoal Agents Phase 4
12 Antiparasitic Agents Phase 4
13 Antimalarials Phase 4
14 Anti-Infective Agents Phase 4
15 Antiviral Agents Phase 4
16 Anthelmintics Phase 4
17
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
18
Pyrimethamine Approved, Investigational, Vet_approved Phase 2, Phase 3 58-14-0 4993
19
Sulfadoxine Approved, Investigational Phase 2, Phase 3 2447-57-6 17134
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
21
Lactitol Investigational Phase 3 585-86-4, 585-88-6 493591
22 Renal Agents Phase 2, Phase 3
23 Vitamin B Complex Phase 2, Phase 3
24 Folic Acid Antagonists Phase 2, Phase 3
25 Anti-Infective Agents, Urinary Phase 2, Phase 3
26 Vitamin B9 Phase 2, Phase 3
27 Folate Phase 2, Phase 3
28
chloroquine Approved, Investigational, Vet_approved 54-05-7 2719
29 Fanasil, pyrimethamine drug combination
30 Amodiaquine, artesunate drug combination
31 Antirheumatic Agents
32 Chloroquine diphosphate 50-63-5

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Efficacy of Artesunate Monotherapy and Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Central Vietnam Unknown status NCT02604966 Phase 4 Artesunate (AS) group;DHA - PPQ group
2 A Multicentre Randomised Comparative Clinical Trial of the Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine (Coartem®) for the Treatment of Uncomplicated Childhood Plasmodium Falciparum Malaria in Zanzibar Completed NCT03768908 Phase 4 Artemether-lumefantrine;Artesunate + Amodiaquine
3 Efficacy and Safety of Artesunate + Amodiaquine Combined With a Single Low Dose of Primaquine (0.25 mg/kg) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Zanzibar Completed NCT03773536 Phase 4 Artesunate-amodiaquine given with single low dose primaquine
4 Evaluation of the Efficacy of Artemisinin Combination Therapy in Kenya Unknown status NCT01899820 Phase 3 Artemether lumefantrine;Dihydroartemisinin piperaquine
5 An Open-label Randomized Controlled Trial to Evaluate the Effectiveness and Safety of a 3 Day Versus 5 Day Course of Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria in Myanmar Completed NCT02020330 Phase 3 Artemether-lumefantrine 3 days;Artemether-lumefantrine 5 days
6 Anti-malarial Drug Resistance in Cameroon: Therapeutic Efficacy and Biological Markers of Resistance Completed NCT00146718 Phase 2, Phase 3 Amodiaquine and Sulphadoxine/Pyrimethamine
7 Phase III Clinical Trials of Artemisinin-based Combination Therapy in Cameroon Completed NCT00297882 Phase 3 Artemether-Lumefantrine , Amodiaquine-Artesunate
8 Efficacy and Safety of Artesunate+Sulphadoxine-Pyrimethamine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malaria Control Center Asadabad in Kunar Province of Afghanistan Unknown status NCT01707199 Artesunate + Sulphadoxine-pyrimethamine
9 Efficacy of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium Falciparum Malaria in Pweto, Democratic Republic of Congo, 2008 Completed NCT01567423 ASAQ Winthrop® Sanofi Aventis;Coartem®, Novartis
10 A Study of the Impact of Insecticide-treated Curtains on the Prevalence of Antimalarial Drug Resistance in Children With Uncomplicated Malaria in Burkina Faso Completed NCT00169078 Chloroquine

Search NIH Clinical Center for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 2

Genetic Tests for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Anatomical Context for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

MalaCards organs/tissues related to Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 2:

40
Bone, T Cells, Testes, Placenta, Myeloid, B Cells, Salivary Gland

Publications for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Articles related to Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 2:

(show top 50) (show all 466)
# Title Authors PMID Year
1
Molecular detection and phylogenetic analysis of canine tick-borne pathogens from Korea. 61
31839473 2020
2
Prevalence and molecular characterization of Anaplasma phagocytophilum in roe deer (Capreolus capreolus) from Spain. 61
31822398 2020
3
Molecular detection and genetic diversity of Anaplasma marginale based on the major surface protein genes in Thailand. 61
31953063 2020
4
Monitoring of efficacy, tolerability and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambaréné, Gabon: an open-label clinical trial. 61
31842893 2019
5
Presence of Roe Deer Affects the Occurrence of Anaplasma phagocytophilum Ecotypes in Questing Ixodes ricinus in Different Habitat Types of Central Europe. 61
31783486 2019
6
Genetic polymorphism of merozoite surface proteins 1 and 2 of Plasmodium falciparum in the China-Myanmar border region. 61
31744492 2019
7
Development of nematode resistance in Arabidopsis by HD-RNAi-mediated silencing of the effector gene Mi-msp2. 61
31757987 2019
8
Insight of diagnostic performance using B-cell epitope antigens derived from triple P44-related proteins of Anaplasma phagocytophilum. 61
31182246 2019
9
Human granulocytic anaplasmosis in Kinmen, an offshore island of Taiwan. 61
31539395 2019
10
Characterization of Glycoproteins of Native 19kDa C-Terminal Merozoite Surface Protein-1 from Native Antigen of Plasmodium falciparum. 61
31879671 2019
11
Immunogenicity of a recombinant fusion construct composed of intrinsically unstructured, low polymorphic segments derived from merozoite surface protein 2 and trophozoite exported protein 1. 61
31358409 2019
12
A suite of kinetically superior AEP ligases can cyclise an intrinsically disordered protein. 61
31346249 2019
13
High-Complexity Plasmodium falciparum Infections, North Central Nigeria, 2015-2018. 61
31211682 2019
14
Novel variants of the newly emerged Anaplasma capra from Korean water deer (Hydropotes inermis argyropus) in South Korea. 61
31345253 2019
15
Severe oxidative stress in sickle cell disease patients with uncomplicated Plasmodium falciparum malaria in Kampala, Uganda. 61
31288760 2019
16
Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort. 61
31185998 2019
17
The Diversity, Multiplicity of Infection and Population Structure of P. falciparum Parasites Circulating in Asymptomatic Carriers Living in High and Low Malaria Transmission Settings of Ghana. 61
31181699 2019
18
Immunization with merozoite surface protein 2 fused to a Plasmodium-specific carrier protein elicits strain-specific and strain-transcending, opsonizing antibody. 61
31227760 2019
19
Sub-microscopic Plasmodium falciparum infections in matched peripheral, placental and umbilical cord blood samples from asymptomatic Congolese women at delivery. 61
30836060 2019
20
Molecular Detection and Characterization of p44/msp2 Multigene Family of Anaplasma phagocytophilum from Haemaphysalis longicornis in Mie Prefecture, Japan. 61
30700658 2019
21
Analysis of antibody responses to selected Plasmodium falciparum merozoite surface antigens in mild and cerebral malaria and associations with clinical outcomes. 61
30580455 2019
22
Bartonella and Rickettsia Infections in Haematophagous Spinturnix myoti Mites (Acari: Mesostigmata) and their Bat Host, Myotis myotis (Yangochiroptera: Vespertilionidae), from Poland. 61
30151669 2019
23
Diversity of Anaplasma species in cattle in Mozambique. 61
30833198 2019
24
Predominant Shift of Different P44-Expressing Anaplasma phagocytophilum in Infected HL-60, THP-1, NB4, and RF/6A Cell Lines. 61
30381676 2019
25
Comparison of msp genotyping and a 24 SNP molecular assay for differentiating Plasmodium falciparum recrudescence from reinfection. 61
30885193 2019
26
An Acid Up-Regulated Surface Protein of Lactobacillus paracasei Strain GCRL 46 is Phylogenetically Related to the Secreted Glucan- (GpbB) and Immunoglobulin-Binding (SibA) Protein of Pathogenic Streptococci. 61
30935131 2019
27
Longitudinal tracking and quantification of individual Plasmodium falciparum clones in complex infections. 61
30833657 2019
28
Molecular detection, characterization of Anaplasma spp. in domestic cats from Rio de Janeiro state. 61
30615856 2019
29
Segmental Variation in a Duplicated msp2 Pseudogene Generates Anaplasma marginale Antigenic Variants. 61
30455197 2019
30
Interaction of merozoite surface protein 2 with lipid membranes. 61
30588612 2019
31
Genetically diverse Plasmodium falciparum infections, within-host competition and symptomatic malaria in humans. 61
30644435 2019
32
Modulation of the aggregation of an amyloidogenic sequence by flanking-disordered region in the intrinsically disordered antigen merozoite surface protein 2. 61
30443712 2019
33
A Multi-Pathogen Screening of Captive Reindeer (Rangifer tarandus) in Germany Based on Serological and Molecular Assays. 61
31921918 2019
34
Enhancing hydrogen production through anaerobic co-digestion of fruit waste with biosolids. 61
30729839 2019
35
Efficacy of Artemisinin Base Combination Therapy and Genetic Diversity of Plasmodium falciparum from Uncomplicated Malaria Falciparum Patient in District of Pesawaran, Province of Lampung, Indonesia. 61
31123479 2019
36
The impact of early life exposure to Plasmodium falciparum on the development of naturally acquired immunity to malaria in young Malawian children. 61
30658632 2019
37
Molecular Detection and Phylogenetic Analysis of Anaplasma phagocytophilum in Horses in Korea. 61
30630276 2018
38
Characterization of Plasmodium falciparum structure in Nigeria with malaria SNPs barcode. 61
30558627 2018
39
Genetic diversity and allele frequencies of Plasmodium falciparum msp1 and msp2 in parasite isolates from Bioko Island, Equatorial Guinea. 61
30526609 2018
40
Diagnosis and molecular characteristics of human infections caused by Anaplasma phagocytophilum in South Korea. 61
30353471 2018
41
High proportions of pfhrp2 gene deletion and performance of HRP2-based rapid diagnostic test in Plasmodium falciparum field isolates of Odisha. 61
30373573 2018
42
The prevalence of submicroscopic Plasmodium falciparum gametocyte carriage and multiplicity of infection in children, pregnant women and adults in a low malaria transmission area in Southern Ghana. 61
30223841 2018
43
Molecular detection of Anaplasma phagocytophilum-like Anaplasma spp. and pathogenic A. Phagocytophilum in cattle from South Korea. 61
29653174 2018
44
Association of Antibodies to VAR2CSA and Merozoite Antigens with Pregnancy Outcomes in Women Living in Yaoundé, Cameroon. 61
29986889 2018
45
Cytophilic Antibodies Against Key Plasmodium falciparum Blood Stage Antigens Contribute to Protection Against Clinical Malaria in a High Transmission Region of Eastern India. 61
29733355 2018
46
Identifying Recrudescent Plasmodium falciparum in Treated Malaria Patients by Real-time PCR and High Resolution Melt Analysis of Genetic Diversity. 61
29973679 2018
47
Human Immunization With a Polymorphic Malaria Vaccine Candidate Induced Antibodies to Conserved Epitopes That Promote Functional Antibodies to Multiple Parasite Strains. 61
29584918 2018
48
Anaplasma species detected in Haemaphysalis longicornis tick from China. 61
29567147 2018
49
Plasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina Faso. 61
29843783 2018
50
Targeting the GPI biosynthetic pathway. 61
29484956 2018

Variations for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Expression for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Search GEO for disease gene expression data for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone with or Without Frontotemporal Dementia 2.

Pathways for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

GO Terms for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

Sources for Inclusion Body Myopathy with Early-Onset Paget Disease of Bone...

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....